Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients
- Conditions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 301
- Registration Number
- NCT01211678
- Locations
- 🇺🇸
Research Site, Franklin, Wisconsin, United States
Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
- Conditions
- Interventions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Biogen
- Target Recruit Count
- 3
- Registration Number
- NCT01211665
- Locations
- 🇩🇪
Research Site, Wurzburg, Germany
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
- Conditions
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT01211639
- Locations
- 🇺🇸
Central Neurology, Hastings, Nebraska, United States
🇺🇸North Central Neurology Associates, Cullman, Alabama, United States
🇺🇸Rocky Mountain MS Center at Anschutz Medical Campus University Colorado Denver, Aurora, Colorado, United States
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
- Conditions
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 7726
- Registration Number
- NCT01185717
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
- Conditions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT01181089
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT01181115
- Locations
- 🇨🇳
Research Site, Xi'an, China
First-in-Human Study of PF-04958242 in Healthy Volunteers
- First Posted Date
- 2010-07-09
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT01159483
- Locations
- 🇸🇬
Research Site, Singapore, Singapore
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 108
- Registration Number
- NCT01156311
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance
- Conditions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 383
- Registration Number
- NCT01156298
- Locations
- 🇺🇸
Research Site, Buffalo, New York, United States
Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT01132703
- Locations
- 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States